Neoadjuvant GOLP therapy significantly enhances event-free survival in patients with resectable high-risk intrahepatic cholangiocarcinoma.

• Median event-free survival was 18.0 months with GOLP, compared to 8.7 months in the control group (p<0.001).
• Overall survival at 24 months was 79% for the neoadjuvant group vs. 61% for controls (hazard ratio 0.43).

Expect lower-grade adverse events overall, with 97% experiencing any adverse event in the neoadjuvant group.

• Grade 3 or higher adverse events occurred in 28% of patients during neoadjuvant treatment, without treatment-related deaths.